Leukapheresis Market to Reach USD 135.57 Bn by 2032 at 7.5% CAGR

Market Overview

The Leukapheresis Market was valued at exactly USD 81.71 Bn in 2025 and is forecast to reach USD 135.57 Bn by 2032, expanding at a CAGR of 7.5% during 2026–2032, according to Maximize Market Research. Leukapheresis separates white blood cells from blood while returning remaining components to circulation, making it important across therapeutic procedures, cell collection, research workflows and advanced immunotherapy development. It is a specialized form of apheresis focused on separating leukocytes from a blood sample while preserving the remaining circulating components.

Download PDF Brochure: https://www.maximizemarketresearch.com/request-sample/13729/

Growth is supported by the rising incidence and prevalence of leukemia, increasing blood donations and expanding demand for leukopaks. MMR also identifies adoption of leukapheresis for white blood cell isolation and cell-based immunotherapy development as a key force behind research demand. High procedure and leukopak costs, potential therapeutic complications and stringent leukocyte donor recruitment requirements remain important restraints. These barriers are specifically identified by MMR as factors that may hamper overall growth during the forecast period across the global market.

Key Growth Drivers Fueling the Leukapheresis Market

Rising leukemia burden: MMR identifies increasing leukemia incidence and prevalence as a core demand driver. This supports therapeutic procedures and associated blood-component workflows.

Growing demand for leukopaks: Clinical research increasingly depends on leukocyte-rich starting material. MMR links this trend directly with stronger collection and research demand.

Cell-based immunotherapy development: Research use is expanding as laboratories isolate white blood cells for cell-based immunotherapies. CAR-T activity and regenerative medicine research are particularly relevant to Asia Pacific growth.

Blood donation activity: Increasing blood donations support collection volumes and the broader apheresis ecosystem. MMR cites this factor behind regional demand, especially in North America and Europe.

Technology and strategic collaboration: Producers are pursuing mergers, collaborations, partnerships and technological product launches to expand portfolios. This strengthens infrastructure around cell separation, collection and downstream cell-therapy workflows.

Market Segmentation — By Type, Application & End-Use

The Leukapheresis Market is segmented by type, application and end user. MMR’s public page lists the categories below but does not disclose numeric segment shares; the application share is displayed only as “xx%,” so no substitute percentage is used.

• By Type: Leukapheresis Devices, including Apheresis Devices, Leukapheresis Columns & Cell Separators and Leukoreduction Filters; and Leukapheresis Disposables.
• By Application: Research Applications; Therapeutic Applications.
• By End User: Blood Component Providers and Blood Centers; Academic and Research Institutes; Pharmaceutical and Biotechnology Companies; Hospitals and Transfusion Centers.

Research Applications is the dominant application identified by MMR for 2025. Its leadership is linked to increasing use of leukapheresis for isolating white blood cells and developing cell-based immunotherapies.

Regional Analysis — Where Is the Leukapheresis Market Growing Fastest?

United States

MMR places the United States within North America, the leading region in 2025. Regional demand is supported by blood donations, leukemia prevalence and leukopaks in clinical research; the public summary gives no separate U.S. market share.

United Kingdom

The United Kingdom is included within Europe. MMR expects Europe to remain a major market alongside North America, supported by blood donation activity, leukemia-related demand and leukopak use; no UK-only share is disclosed.

Germany

Germany is also part of MMR’s European coverage and participates in the same regional demand environment. MMR cites Fresenius among major industry participants but publishes no Germany-specific market figure.

Japan

Japan falls within Asia Pacific, which MMR identifies as the fastest-growing regional group. Growth is tied to regenerative medicine research, CAR-T clinical trials, pharma and biotech presence and improving healthcare access.

South Korea

South Korea is included in Asia Pacific. MMR points to regenerative medicine, cell-therapy trials, industry presence and healthcare access as regional growth drivers, without publishing a country share.

China

China is covered within Asia Pacific and therefore sits inside the region expected to grow fastest. MMR attributes regional momentum to regenerative medicine research, CAR-T activity, pharma and biotech presence and better healthcare access.

India

India is another Asia Pacific country in the MMR scope. Its opportunity is framed by the same regional expansion in regenerative medicine, clinical cell therapy and healthcare access; no India-only size is publicly disclosed.

North America is the dominant region in 2025, while Asia Pacific is the fastest-growing region. Based on MMR’s stated growth drivers, Asia Pacific is also the clearest regional investment focus, though the public summary does not name one country as the single top investment hotspot.

Competitive Landscape  Leading Companies in the Leukapheresis Market

1. Asahi Kasei Medical  Listed by MMR among key companies competing across leukapheresis and related separation solutions.
2. Haemonetics  Included among major participants serving blood collection and apheresis workflows.
3. Terumo BCT  MMR identifies Terumo BCT as the market leader, citing innovation, production expansion, portfolio development and strategic transactions.
4. STEMCELL Technologies  Listed as a key participant relevant to research and cell-processing demand.
5. Macopharma  Included among the principal competitors in MMR’s market landscape.

Download PDF Brochure: https://www.maximizemarketresearch.com/request-sample/13729/

Recent Developments & Strategic Moves in the Leukapheresis Market

• Acquisition: On 13 May 2026, OrganaBio acquired substantially all operating assets of Excellos Inc., expanding its cell-therapy development and leukapheresis service footprint.
• Strategic partnership: On 14 January 2026, Fresenius Kabi entered a development agreement with TQ Therapeutics around cell-selection technology for scalable cell-therapy production closer to the collection point.
• Infrastructure investment: MMR reports BBG Advanced Therapies’ mobile leukapheresis center and Northwest Biotherapeutics’ dedicated London clinic as moves to expand access and relieve collection-capacity constraints.
• Product and workflow innovation: Terumo BCT has advanced automated cell-therapy workflows and launched an APAC cell-and-gene-therapy ecosystem blueprint supporting scalable, repeatable delivery.
• AI and government capacity planning: Recent peer-reviewed work applies machine learning to pre-collection variables for leukapheresis planning, while the UK government’s apheresis capacity review calls for nationally coordinated capacity planning as advanced therapies increase service pressure.

AI & Digital Transformation Impact on Leukapheresis Market

AI is beginning to change the Leukapheresis Market by moving collection planning toward data-assisted prediction and standardized workflows. Machine learning can use routine pre-collection information to estimate collection efficiency, supporting more consistent procedure planning and cell-therapy manufacturing inputs.

Automation is also reshaping downstream processing. Closed, integrated platforms can connect apheresis-derived starting material with cell selection, activation, transduction and expansion, reducing manual handoffs and supporting repeatability. The opportunity is to combine collection hardware, disposables, digital process control and scalable cell-manufacturing infrastructure.

Future Outlook  Investment Opportunities & Emerging Trends

The future of the Leukapheresis Market is closely linked to cell and gene therapy, regenerative medicine, leukopak demand and scalable collection infrastructure. With MMR forecasting growth from USD 81.71 Bn in 2025 to USD 135.57 Bn by 2032 at 7.5% CAGR, opportunities center on automated collection, cell separation, research and therapeutic workflows, capacity expansion and partnerships linking blood centers with biotechnology companies. Asia Pacific offers the strongest growth momentum, while North America remains the established leader.

Related Reports

Cell Therapy Market https://www.maximizemarketresearch.com/market-report/cell-therapy-market/126471/

Ketamine Treatment Market https://www.maximizemarketresearch.com/market-report/ketamine-treatment-market/216827/

Global 3D Printing Medical Devices Market https://www.maximizemarketresearch.com/market-report/global-3d-printing-medical-devices-market/29471/

Expert Commentary

"According to Komal Patil, Research Manager at Maximize Market Research, 'The Leukapheresis Market is projected to advance from USD 81.71 Bn in 2025 to USD 135.57 Bn by 2032 at a 7.5% CAGR, reinforcing the strategic value of collection capacity and cell-therapy infrastructure. Investment is increasingly aligned with research applications, automation, scalable cell processing and Asia Pacific expansion as the industry supports next-generation immunotherapy workflows.'"

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

Contact Us

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com